Patent · US Active

Mutated immunoglobulin-binding polypeptides

US10501557B2 · kind B2 · utility

8Cited by

4References

31Claims

0Family size

Assignee

GE Healthcare BioProcess R&D AB · SE

Inventors

Gustav Rodrigo · Uppsala, SE
Tomas Bjorkman · Uppsala, SE
Mats Ander · Uppsala, SE

Key dates

Filing date	Nov 16, 2015
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Nov 16, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/065
WIPO fieldChemical engineering
WIPO sectorChemistry

Abstract

An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.